(Q39160111)

9 September 2017

Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation (English)

1 reference

9 September 2017

0 references

6

1 reference

9 September 2017

12

1 reference

9 September 2017

5

Giovanni Corona

1 reference

9 September 2017

16

Mario Maggi

1 reference

9 September 2017

7

Giulia Rastrelli

1 reference

9 September 2017

1

Linda Vignozzi

1 reference

9 September 2017

14

Edoardo Mannucci

1 reference

9 September 2017

2

Mauro Gacci

1 reference

9 September 2017

13

Andrea Tubaro

1 reference

9 September 2017

Ilaria Cellai

3

1 reference

9 September 2017

Raffaella Santi

4

1 reference

9 September 2017

Paolo Comeglio

8

1 reference

9 September 2017

Arcangelo Sebastanelli

9

1 reference

9 September 2017

Elena Maneschi

10

1 reference

9 September 2017

Gabriella Nesi

11

1 reference

9 September 2017

Marco Carini

15

1 reference

9 September 2017

28 November 2012

1 reference

9 September 2017

1 reference

9 September 2017

73

1 reference

9 September 2017

8

1 reference

9 September 2017

789-800

1 reference

Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network

9 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Metabolic factors associated with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Insulin-resistance and benign prostatic hyperplasia: the connection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

The correlation between metabolic syndrome and prostatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

The functional role of reactive stroma in benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Development of diabesity in mice with neuronal deletion of Shp2 tyrosine phosphatase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Testosterone, cardiovascular disease and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Invasive and minimally invasive treatment modalities for lower urinary tract symptoms: what are the relevant differences in randomised controlled trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Holmium laser enucleation versus transurethral resection of the prostate. Are histological findings comparable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Consensus development of a histopathological classification system for chronic prostatic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Redirection of allergen-specific TH2 responses by a modified adenine through Toll-like receptor 7 interaction and IL-12/IFN release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Cytokines and chemokines in follicular fluids and potential of the corresponding embryo: the role of granulocyte colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Testosterone deficiency, insulin resistance and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Testosterone and metabolic syndrome: a meta-analysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Endocrine aspects of male sexual dysfunctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Late-onset hypogonadism syndrome and lower urinary tract symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Prostate tissue androgens: history and current clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Dihydrotestosterone suppresses foam cell formation and attenuates atherosclerosis development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22623

21 January 2018

Identifiers

DOI

10.1002/PROS.22623

1 reference

9 September 2017

1 reference